drugset / Trial / NCT07111013

A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease

NCT07111013

Phase 3 Withdrawn Bausch & Lomb Incorporated
NaSingle-groupOpen-labelTreatment

Summary

A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease

Timeline

Start
2025-12
Primary completion
2027-04
Completion
2027-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Lifitegrast Unknown 5 % Topical
Subject Perfluorohexyloctane Unknown 95 % Topical

Indications